Kelemen Hajnal, Hancu Gabriel, Papp Lajos Attila
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Medicine and Pharmacy Science and Technology from Târgu Mureș, Romania.
Biomed Chromatogr. 2019 Jul;33(7):e4528. doi: 10.1002/bmc.4528. Epub 2019 Apr 21.
Ticagrelor is an orally administered platelet aggregation inhibitor with a cyclopentyl-triazolopyrimidine structure; it is a selective reversible P2Y12 receptor antagonist, which prevents P2Y12-mediated and ADP-mediated platelet activation and aggregation. It is used to reduce the rate of cardiovascular death, myocardial infarction and stroke in patients with acute coronary syndrome or history of myocardial infarction. Several analytical methods have been published for the determination of ticagrelor in pharmaceuticals and biological materials by spectrophotometry, high-performance liquid chromatography with ultraviolet detection and liquid chromatography coupled with tandem mass spectrometry. The purpose of the current review is to provide a systematic survey of the analytical techniques used for the determination of ticagrelor since its introduction in therapy until today.
替格瑞洛是一种口服的血小板聚集抑制剂，具有环戊基 - 三唑并嘧啶结构；它是一种选择性可逆P2Y12受体拮抗剂，可防止P2Y12介导和ADP介导的血小板活化与聚集。它用于降低急性冠状动脉综合征或心肌梗死病史患者的心血管死亡、心肌梗死和中风发生率。已有几种分析方法发表，用于通过分光光度法、带紫外检测的高效液相色谱法以及液相色谱 - 串联质谱法测定药品和生物材料中的替格瑞洛。本综述的目的是对自替格瑞洛用于治疗以来直至今日所使用的测定其含量的分析技术进行系统综述。
